-
New Hope for Ovarian Cancer: BioInvent’s BI-1808 Receives FDA Fast Track Designation
A Major Milestone in Cancer Research BioInvent International AB recently announced a significant breakthrough in oncology: the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to their investigational drug candidate, BI-1808. This development marks a hopeful step forward for patients battling ovarian cancer. What is BI-1808? BI-1808 is a specialized monoclonal antibody…
-
Oncoinvent Reaches Key Milestone in Phase 2 Ovarian Cancer Trial for Radspherin®
A Significant Step Forward in Ovarian Cancer Research Oncoinvent AS, a clinical-stage radiopharmaceutical company, has announced a major achievement in its ongoing clinical development program. The company has officially reached the 50% recruitment milestone in its Phase 2a clinical trial evaluating Radspherin®, a novel alpha-emitting radioactive microsphere treatment designed for patients with advanced ovarian cancer.…